Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

424 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study.
O'Hara J, Finnegan A, Dhillon H, Ruiz-Casas L, Pedra G, Franks B, Morgan G, Hebditch V, Jönsson B, Mabhala M, Reic T, Van Thiel I, Ratziu V, Romero-Gomez M, Bugianesi E, Schattenberg JM, Anstee QM. O'Hara J, et al. Among authors: ratziu v. JHEP Rep. 2020 Jul 15;2(5):100142. doi: 10.1016/j.jhepr.2020.100142. eCollection 2020 Oct. JHEP Rep. 2020. PMID: 32775976 Free PMC article.
TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.
Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM. Liu YL, et al. Among authors: ratziu v. Nat Commun. 2014 Jun 30;5:4309. doi: 10.1038/ncomms5309. Nat Commun. 2014. PMID: 24978903 Free PMC article.
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L, Romero-Gomez M, Boursier J, Abdelmalek M, Caldwell S, Drenth J, Anstee QM, Hum D, Hanf R, Roudot A, Megnien S, Staels B, Sanyal A; GOLDEN-505 Investigator Study Group. Ratziu V, et al. Gastroenterology. 2016 May;150(5):1147-1159.e5. doi: 10.1053/j.gastro.2016.01.038. Epub 2016 Feb 11. Gastroenterology. 2016. PMID: 26874076 Free article. Clinical Trial.
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, Trauner M, Romero Gomez M, Oliveira C, Day C, Dufour JF, Bellentani S, Ngo Y, Traussnig S, Perazzo H, Deckmyn O, Bedossa P, Ratziu V, Poynard T; FLIP Consortium and the FibroFrance Group. Munteanu M, et al. Among authors: ratziu v. Aliment Pharmacol Ther. 2016 Oct;44(8):877-89. doi: 10.1111/apt.13770. Epub 2016 Aug 23. Aliment Pharmacol Ther. 2016. PMID: 27549244 Free PMC article.
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.
McPherson S, Hardy T, Dufour JF, Petta S, Romero-Gomez M, Allison M, Oliveira CP, Francque S, Van Gaal L, Schattenberg JM, Tiniakos D, Burt A, Bugianesi E, Ratziu V, Day CP, Anstee QM. McPherson S, et al. Among authors: ratziu v. Am J Gastroenterol. 2017 May;112(5):740-751. doi: 10.1038/ajg.2016.453. Epub 2016 Oct 11. Am J Gastroenterol. 2017. PMID: 27725647 Free PMC article.
Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science.
Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, Dimick-Santos L, Friedman SL, Greene K, Kleiner DE, Megnien S, Neuschwander-Tetri BA, Ratziu V, Schabel E, Miller V, Sanyal AJ; Liver Forum Case Definitions Working Group. Siddiqui MS, et al. Among authors: ratziu v. Hepatology. 2018 May;67(5):2001-2012. doi: 10.1002/hep.29607. Epub 2018 Feb 22. Hepatology. 2018. PMID: 29059456 Free PMC article.
Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K. Younossi ZM, et al. Among authors: ratziu v. Hepatology. 2018 Jul;68(1):361-371. doi: 10.1002/hep.29724. Hepatology. 2018. PMID: 29222911 Free PMC article.
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
Younossi ZM, Loomba R, Anstee QM, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Goodman ZD, Chalasani NP, Kowdley KV, George J, Lindor K. Younossi ZM, et al. Among authors: ratziu v. Hepatology. 2018 Jul;68(1):349-360. doi: 10.1002/hep.29721. Hepatology. 2018. PMID: 29222917 Free PMC article.
NAFLD: The evolving landscape.
George J, Anstee Q, Ratziu V, Sanyal A. George J, et al. Among authors: ratziu v. J Hepatol. 2018 Feb;68(2):227-229. doi: 10.1016/j.jhep.2017.11.016. Epub 2017 Dec 6. J Hepatol. 2018. PMID: 29223512 No abstract available.
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.
Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC, Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Estes C, et al. Among authors: ratziu v. J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8. J Hepatol. 2018. PMID: 29886156 Free article.
424 results